logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Which outcome measures should be use in rheumatoid arthritis clinical trials ? Clinical and quality-of-life measures'responsiveness to treatment in a randomized controlled trial.

    Article - En anglais

    Objective

    To determine the discriminant validity of the core set of outcome measures proposed by the American College of Rheumatology (ACR) and the Outcome Measures in Clinical Trials (OMERACT) conference committee to be used in clinical trials of rheumatoid arthritis (RA).

    Methods

    Utilizing data from a multicenter randomized double-blind clinical trial of low-dose cyclosporine and placebo in RA, we estimated the relative efficiency (RE) of measures to detect a treatment effect (relative to tender joint count, which was assigned a value of 1).

    Four pain measures (10-cm visual analog scale [VAS], 5-point categorical scale, Health Assessment Questionnaire [HAQ] pain index, Arthritis Impact Measurement Scales [AIMS] pain score) and 3 quality-of-life measures (Problem Elicitation Technique [PET], HAQ, AIMS) were compared.

    Results

    Physician and patient global measures were the most responsive instruments, although neither was statistically superior to tender joint count.

    Swollen joint count, grip strength, pain measured on a 10-cm VAS, and functional status as measured by the PET and HAQ were all of intermediate responsiveness.

    Morning stiffness, 5-point pain scale, and erythrocyte sedimentation rate were the least responsive instruments.

    Conclusion

    This study provides further evidence to support the core set of outcome measures proposed by the ACR and OMERACT.

    Mots-clés Pascal : Polyarthrite rhumatoïde, Chronique, Maladie autoimmune, Rhumatisme inflammatoire, Immunopathologie, Système ostéoarticulaire pathologie, Pronostic, Homme, Chimiothérapie, Immunomodulateur, Antirhumatismal, Evaluation, Efficacité traitement, Echelle évaluation, Ciclosporine, Validation test, Méthode mesure, Qualité vie, Essai clinique

    Mots-clés Pascal anglais : Rheumatoid arthritis, Chronic, Autoimmune disease, Inflammatory joint disease, Immunopathology, Diseases of the osteoarticular system, Prognosis, Human, Chemotherapy, Immunomodulator, Antirheumatic agent, Evaluation, Treatment efficiency, Evaluation scale, Test validation, Measurement method, Quality of life, Clinical trial

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0041205

    Code Inist : 002B15D. Création : 01/03/1996.